Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Phase 1 Recruiting
46 enrolled
Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)
Phase 1 Recruiting
33 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
Phase 1 Recruiting
11 enrolled
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 Recruiting
54 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
450 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
45 enrolled
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Phase 1 Recruiting
90 enrolled
Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas
Phase 1 Recruiting
22 enrolled
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
Phase 1 Recruiting
60 enrolled
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
Phase 1 Recruiting
56 enrolled
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Phase 1 Recruiting
694 enrolled
LUMIRAY
Phase 1 Recruiting
30 enrolled
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
Phase 1 Recruiting
6 enrolled
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1 Recruiting
40 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
STEALTH-001
Phase 1 Recruiting
60 enrolled
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Phase 1 Recruiting
310 enrolled
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
113 enrolled
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Phase 1 Recruiting
70 enrolled
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Phase 1 Recruiting
100 enrolled
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Phase 1 Recruiting
150 enrolled
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Phase 1 Recruiting
40 enrolled
Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer
Phase 1 Recruiting
6 enrolled
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Phase 1 Recruiting
267 enrolled
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Phase 1 Recruiting
124 enrolled
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Phase 1 Recruiting
138 enrolled
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Phase 1 Recruiting
110 enrolled
NEXUS-01
Phase 1 Recruiting
420 enrolled
Study of CHS-114 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
87 enrolled
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Phase 1 Recruiting
18 enrolled
STELLAR-002
Phase 1 Recruiting
1,314 enrolled
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
Phase 1 Recruiting
24 enrolled
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
Phase 1 Recruiting
30 enrolled
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
Phase 1 Recruiting
30 enrolled
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Phase 1 Recruiting
40 enrolled
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 Recruiting
150 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
177Lu-CTR-FAPI for the Treatment of Thyroid Cancer
Phase 1 Recruiting
12 enrolled
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 Recruiting
714 enrolled
EGRET
Phase 1 Recruiting
403 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Phase 1 Recruiting
170 enrolled
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Phase 1 Recruiting
220 enrolled
GUARDIAN-101
Phase 1 Recruiting
90 enrolled
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Phase 1 Recruiting
150 enrolled
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
216 enrolled
VISTA
Phase 1 Recruiting
45 enrolled
A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
250 enrolled